Literature DB >> 20818340

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume.

Theo H van der Kwast1, Mahul B Amin, Athanase Billis, Jonathan I Epstein, David Griffiths, Peter A Humphrey, Rodolfo Montironi, Thomas M Wheeler, John R Srigley, Lars Egevad, Brett Delahunt.   

Abstract

The 2009 International Society of Urological Pathology consensus conference in Boston made recommendations regarding the standardization of pathology reporting of radical prostatectomy specimens. Issues relating to the substaging of pT2 prostate cancers according to the TNM 2002/2010 system, reporting of tumor size/volume and zonal location of prostate cancers were coordinated by working group 2. A survey circulated before the consensus conference demonstrated that 74% of the 157 participants considered pT2 substaging of prostate cancer to be of clinical and/or academic relevance. The survey also revealed a considerable variation in the frequency of reporting of pT2b substage prostate cancer, which was likely a consequence of the variable methodologies used to distinguish pT2a from pT2b tumors. Overview of the literature indicates that current pT2 substaging criteria lack clinical relevance and the majority (65.5%) of conference attendees wished to discontinue pT2 substaging. Therefore, the consensus was that reporting of pT2 substages should, at present, be optional. Several studies have shown that prostate cancer volume is significantly correlated with other clinicopathological features, including Gleason score and extraprostatic extension of tumor; however, most studies fail to demonstrate this to have prognostic significance on multivariate analysis. Consensus was reached with regard to the reporting of some quantitative measure of the volume of tumor in a prostatectomy specimen, without prescribing a specific methodology. Incorporation of the zonal and/or anterior location of the dominant/index tumor in the pathology report was accepted by most participants, but a formal definition of the identifying features of the dominant/index tumor remained undecided.

Entities:  

Mesh:

Year:  2010        PMID: 20818340     DOI: 10.1038/modpathol.2010.156

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  51 in total

1.  The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Authors:  Charles C Guo; Yan Wang; Li Xiao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2011-09-19       Impact factor: 3.466

2.  Automatic cancer detection on digital histopathology images of mid-gland radical prostatectomy specimens.

Authors:  Wenchao Han; Carol Johnson; Andrew Warner; Mena Gaed; Jose A Gomez; Madeleine Moussa; Joseph Chin; Stephen Pautler; Glenn Bauman; Aaron D Ward
Journal:  J Med Imaging (Bellingham)       Date:  2020-07-16

3.  Comparison of two commonly used methods in measurement of cancer volume in prostate biopsy.

Authors:  Viharkumar Patel; Samuel Hubbard; Wei Huang
Journal:  Int J Clin Exp Pathol       Date:  2020-04-01

Review 4.  [Diagnostics of radical prostatectomy specimens. Results of the 2009 consensus conference of the International Society of Urological Pathology].

Authors:  G Kristiansen; J R Srigley; B Delahunt; L Egevad
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

5.  Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy.

Authors:  Georg Müller; Malte Rieken; Gernot Bonkat; Joel Roman Gsponer; Tatjana Vlajnic; Christian Wetterauer; Thomas C Gasser; Stephen F Wyler; Alexander Bachmann; Lukas Bubendorf
Journal:  Virchows Arch       Date:  2014-08-17       Impact factor: 4.064

6.  Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer.

Authors:  Su-Jin Shin; Cheol Keun Park; Sung Yoon Park; Won Sik Jang; Joo Yong Lee; Young Deuk Choi; Nam Hoon Cho
Journal:  Virchows Arch       Date:  2016-06-15       Impact factor: 4.064

7.  In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Authors:  Yujiro Ito; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

8.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Authors:  Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 9.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

10.  Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer.

Authors:  Wen-Jun Xiao; Yu Zhu; Yao Zhu; Bo Dai; Ding-Wei Ye
Journal:  World J Urol       Date:  2018-01-25       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.